A novel strategy for the treatment of drug-resistant ovarian cancer combines chemotherapy to increase immunogenic cell death and virally delivered CXCR4 to reverse the immunosuppressive tumor microenvironment (242). This evidence concerns the gene CXCR4 and neoplasm.